DE172932C - - Google Patents
Info
- Publication number
- DE172932C DE172932C DENDAT172932D DE172932DA DE172932C DE 172932 C DE172932 C DE 172932C DE NDAT172932 D DENDAT172932 D DE NDAT172932D DE 172932D A DE172932D A DE 172932DA DE 172932 C DE172932 C DE 172932C
- Authority
- DE
- Germany
- Prior art keywords
- sodium
- theobromine
- formate
- diuretic
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HLBBKKJFGFRGMU-UHFFFAOYSA-M Sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 5
- 239000004280 Sodium formate Substances 0.000 claims description 5
- 235000019254 sodium formate Nutrition 0.000 claims description 5
- -1 sodium theobromine sodium formate Chemical compound 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 18
- 229960004559 Theobromine Drugs 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 230000001396 anti-anti-diuretic Effects 0.000 description 7
- 230000001882 diuretic Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- OZHPKSFNBCNLER-UHFFFAOYSA-M sodium;3,7-dimethyl-6-oxopurin-2-olate Chemical compound [Na+].CN1C(=O)[N-]C(=O)C2=C1N=CN2C OZHPKSFNBCNLER-UHFFFAOYSA-M 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- PUZIEUCZZUYNJQ-UHFFFAOYSA-M N1C(=O)N(C)C=2N=CN(C)C2C1=O.C(=O)[O-].[Na+] Chemical compound N1C(=O)N(C)C=2N=CN(C)C2C1=O.C(=O)[O-].[Na+] PUZIEUCZZUYNJQ-UHFFFAOYSA-M 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 1
- 229910020936 NaC Inorganic materials 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- ZDPALFHDPFYJDY-UHFFFAOYSA-N [Na].OC=O Chemical compound [Na].OC=O ZDPALFHDPFYJDY-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HBRJTAOFEGTXSY-UHFFFAOYSA-M sodium;2-(3,7-dimethyl-2,6-dioxopurin-1-yl)acetate Chemical compound [Na+].CN1C(=O)N(CC([O-])=O)C(=O)C2=C1N=CN2C HBRJTAOFEGTXSY-UHFFFAOYSA-M 0.000 description 1
- WSRBRQQGWDWSON-UHFFFAOYSA-M sodium;3,7-dimethylpurine-2,6-dione;2-hydroxybenzoate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C WSRBRQQGWDWSON-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE172932C true DE172932C (xx) |
Family
ID=437781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DENDAT172932D Active DE172932C (xx) |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE172932C (xx) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE944518C (de) * | 1950-08-20 | 1956-06-14 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung von Loesungen von in 1, 3-Stellung substituierten Xanthinen |
-
0
- DE DENDAT172932D patent/DE172932C/de active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE944518C (de) * | 1950-08-20 | 1956-06-14 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung von Loesungen von in 1, 3-Stellung substituierten Xanthinen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE172932C (xx) | ||
| DE895769C (de) | Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen | |
| DE604228C (de) | Verfahren zur Darstellung von in Wasser leicht loeslichen Praeparaten der in Wasser schwer bzw. unloeslichen Salze der Chinaalkaloide bzw. von deren waessrigen Loesungen | |
| DE702185C (de) | hen Calciumdoppelsalzen der Ascorbinsaeure | |
| DE633786C (de) | Verfahren zur Herstellung von Komplexverbindungen des 1, 3-Dimethylxanthins | |
| DE261875C (xx) | ||
| DE229575C (xx) | ||
| DE655684C (de) | Verfahren zur Gewinnung von Metallverbindungen der Keratinsaeuren | |
| DE247625C (xx) | ||
| DE268555C (xx) | ||
| AT157575B (de) | Verfahren zur Herstellung von unzersetzt haltbaren, sterilisierbaren Arzneimittellösungen aus der Doppelverbindung Theophyllin-Piperazin. | |
| DE229905C (xx) | ||
| DE738499C (de) | Verfahren zur Darstellung von Additionsverbindungen des Hexamethylentetramins | |
| DE164424C (xx) | ||
| DE430684C (de) | Verfahren zur Herstellung einer basischen Trijodphenol-Wismutverbindung | |
| DE536276C (de) | Verfahren zur Darstellung neuer Alkaloidsalze | |
| DE682021C (de) | Verfahren zur Darstellung haltbarer komplexer Goldverbindungen der Brenzcatechindisulfonsaeure | |
| DE303450C (xx) | ||
| DE630705C (de) | Verfahren zur Darstellung haltbarer injizierbarer Loesungen N-mono-C, C-disubstituierter Barbitursaeuren | |
| DE601995C (de) | Verfahren zur Darstellung von komplexen Antimonverbindungen | |
| DE490400C (de) | Verfahren zur Darstellung von Erdalkalisalzen organischer Arsenverbindungen | |
| DE343150C (de) | Verfahren zur Darstellung von Salzen der Verbindungen von Gerbsaeuren oder Gallussaeure und Milchsaeure | |
| DE415095C (de) | Verfahren zur Herstellung einer in Wasser leicht loeslichen Wismutkomplexverbindung der Chinolinreihe | |
| DE82951C (xx) | ||
| DE272035C (xx) |